NCT06590194View on ClinicalTrials.gov

PH009-1 in Patients With EGFR Mutation Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 10, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

August 31, 2026

Conditions

Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

Interventions

DRUG

PH009-1 tablet

PH009-1 will be administered in fasting state

Trial Locations (1)

519041

Guangdong Provincial People's Hospital, Guangzhou

All Listed Sponsors

lead

Suzhou Puhe Pharmaceutical Technology Co., LTD

INDUSTRY

NCT06590194 - PH009-1 in Patients With EGFR Mutation Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) | Biotech Hunter | Biotech Hunter